Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06225427
Title Gilteritinib for the Treatment of ALK NSCLC
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Michigan Rogel Cancer Center
Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST